AerobiKA®

Oscillating Positive
Expiratory Pressure Therapy System

Empowering COPD Patients

To Breathe Better, Live Better by Reducing Exacerbations[6]

77% of COPD patients have experienced an exacerbation† increasing risk of hospitalization and driving disease progression.[1]

Globally COPD is...

4th leading cause of death[2]



More than **251 million** cases[3]

More than **3 million death**[3]

The **Countdown** to her **next COPD exacerbation** has **already begun**

Acute exacerbations result in:

- ***Decline*** in lung funtion[5]
- ***Poorer quality*** of life[5]
- ***Increased*** mortality[5]
- ***Frequent*** hospital admissions, relapses and readmissions[5]

1 in 5 patients **hospitalized for a COPD exacerbation** require **rehospitalization within 30 days**[6]

AerobiKA*

Oscillating Positive
Expiratory Pressure Therapy System

The ***Aerobika**** device works to address the structural and functional challenges in the airways of patients with COPD.

In a real-world study with COPD patients with chronic bronchitis, the ***Aerobika**** device was clinically proven to reduce exacerbations, and is **clinically proven to reduce exacerbations, increase lung function and improve patient quality of life.**[6]

How the ***Aerobika**** **Oscillating Positive Expiratory Pressure (OPEP)** device works

Designed to address the structural and functional challenges in post-exacerbation airways



Mucus clearance can reduce breathlessness, prevent recurring infection, reduce exacerbations, hospitalizations and improve quality of life.[8]

Reduces COPD exacerbations
by 28% in the critical 30 day period[6]



Real world study measured the rate of early (30-day) moderate-to-severe exacerbations and related costs in COPD patients with chronic bronchitis. Moderate-to-severe exacerbation is defined as a hospitalization or an emergency department visit.

Improves **Quality of Life** in **COPD Patients**[9]

Responder rate analysis for improvements greater than the Minimum Clinically Important Difference (MCID)



† Randomized cross-over study evaluating four-times daily Aerobika® device use after 3-4 weeks of treatment in COPD patients with chronic bronchitis.
‡ Clinical assessment of COPD patients with chronic bronchitis over 8 weeks of treatment with the Aerobika® OPEP device.
St. George's Respiratory Questionnaire (SGRQ) measures impact on overall health, daily life and perceived well-being in airways disease; MCID≥4
COPD Assessment Test (CAT) assesses impact of COPD on health status; MCID≥2

Improves **Ventilation** in **COPD Patients**[8]

Before
Baseline care (no OPEP/PEP device)

After
Baseline care plus ***Aerobika**** device



Teal colour and intensity show areas with gas distribution. Yellow circles represent areas of greatest change after 3-4 weeks of ***Aerobika**** device use.

Randomized cross-over study evaluating four-times daily ***Aerobika**** device use after 3-4 weeks of treatment in patients with COPD and chronic bronchitis. Hyperpolarized helium-3 (3He) magnetic resonance imaging (MRI) ventilation in representative sputum producer.

Improves **Lung Function** in **COPD Patients**[8]



Randomized cross-over study evaluating four-times daily ***Aerobika****device use after 3-4 weeks of treatment in COPD patients with chronic bronchitis. FVC=forced vital capacity

Efficiency and Effectiveness[10]

- ✔ Oscillations occur from the start through to the end of the breath
- ✔ The amplitude of the oscillations is high and consistent
- ✔ Frequency of the oscillations mimics natural airway cilia movement



Adapted from Meyer and Suggett, poster presented at CHEST 2017.[5]

Percentage of exhaled breath with oscillations

81% ***Aerobika* device***
67% **Acapella Choice†**
62% **Flutter†**

Average oscillation pressure amplitude (cm H_20)

13.9 ***Aerobika* device***
5.8 **Acapella Choice†**
3.0 **Flutter†**

The ***Aerobika**** OPEP device was the most efficient and effective OPEP device tested *in vitro*[10]

*Aerobika** OPEP Device compared to Acapella[11]

Real world evidence among Chronic Obstructive Pulmonary Disease **(COPD)** patients with chronic bronchitis on Hospital Readmissions at 30 Days and 12 Months

n = 619 ***Aerobika**** OPEP Device n = 1857 Acapella

30 Days Results



12 Month Results





COPD Patients Feedback Survey



97% of responders said they would continue to use the ***Aerobika**** device[12]

How to Use



❶ **CLOSE LIPS** around mouthpiece

❷ **INHALE and HOLD** 2-3 seconds

❸ **EXHALE**—slowly, steady, firmly

❹ **REPEAT** and huff cough

Administer for 10 minutes, twice daily.

How to Clean



❶ **WASH** in soapy water

❷ **RINSE** in clean water

❸ **AIR DRY** thoroughly

DISHWASHER SAFE top rack in basket

AerobiKA*

Drug-free

- Handheld mechanical device designed to address the structural and functional challenges in the airways of patients with COPD

Clinically Proven

- **Reduces** exacerbations[6]
- **Improves** lung ventilation and function[6]
- **Improves** patient quality of life[6]

Easy to Use

- Disassembles into 4 parts for ease of cleaning and disinfection
- Position independent
- Inhale and exhale without removing from mouth
- Adjustable resistance settings
- Oscillations are maintained from the start to the end of each breath

Prescribe the ***Aerobika**** device as an add-on to **usual COPD treatment.**
Available behind the counter at retail pharmacy.

Prescription coverage is easy. Pay and Submit.

1. Neil Barnes et al; COPD and exacerbations: Patient insights. BMC Pulmonary Medicine 2013. 2. O'Donnell E Dennis et al; Canadian Thoracic society reco.for the management of COPD. Can Respir J 2008;15 3. All causes readmission to acute care. Canadian institute of health informatics ISBN 978-1-77109-040-7,2012. 4. https://www.lungsask.ca/about-us/news-room/backgrounders-and-information-sheets/copd-fact-sheet last accessed on 14/7/2020. 5. Bourbeau et al; CTS position statement: Pharmacotherapy in patients with COPD. Canadian J. of resp., cric. Care and sleep medicine 2017 vol.1. 6. Burudpakee et al; Pulm Ther 2017 DOI: 10.1007/s41030-017-0027-5 7. Glenn Leemans et al; COPD Functional resp.imaging. International J. of COPD 2020. 8. Svenningsen S. et al. Oscillatory Positive Expiratory Pressure in Chronic Obstructive Pulmonary Disease. COPD 2016;13(1):66-74. 9. Suggett J.; QoL responder rate analysis; SGRQ vs CAT assessment. COPD 10, 2016 UK. 10. Meyers et al; A lab assessment of different OPEP device. CHEST 2017. 11. J. Suggett et al; A retrospective cohort study comparing 2 OPEP devices in patients with COPD. ATS 2020. 12. Harkness H. et al; Survey of Patients Using an OPEP device. Canadian respiratory conf. 2015.

TRUDELL MEDICAL INTERNATIONAL

MEDICAL DESIGN EXCELLENCE AWARDS† 2014 GOLD WINNER

Scan to watch how to use and how to clean